Oramed Pharmaceuticals Inc.
ORMP
$2.74
-$0.01-0.36%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 196.74% | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 196.74% | -- | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -98.07% | -- | -100.00% |
| SG&A Expenses | 11.44% | -10.37% | -17.62% | -20.66% | -29.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.91% | 21.81% | 14.95% | -25.30% | -44.77% |
| Operating Income | 0.40% | -6.26% | -5.89% | 18.95% | 39.61% |
| Income Before Tax | 678.66% | -199.25% | -339.54% | -412.89% | 142.25% |
| Income Tax Expenses | 331.37% | 22.83% | -- | -- | -- |
| Earnings from Continuing Operations | 897.45% | -216.74% | -376.35% | -475.45% | 125.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -39.73% | -45.54% | -81.61% | -90.16% | -87.63% |
| Net Income | 882.13% | -215.82% | -370.07% | -444.98% | 127.30% |
| EBIT | 0.40% | -6.26% | -5.89% | 18.95% | 39.61% |
| EBITDA | -0.32% | -6.96% | -6.34% | 19.17% | 40.16% |
| EPS Basic | 830.65% | -216.68% | -368.44% | -446.70% | 127.23% |
| Normalized Basic EPS | 4.99% | 12.67% | -4.65% | 21.23% | 43.08% |
| EPS Diluted | 863.09% | -224.09% | -382.47% | -473.14% | 124.75% |
| Normalized Diluted EPS | 4.20% | 11.71% | -5.54% | 21.26% | 43.97% |
| Average Basic Shares Outstanding | 1.34% | 1.09% | 1.06% | 1.32% | 1.92% |
| Average Diluted Shares Outstanding | 1.03% | 0.17% | 0.38% | 1.53% | 3.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |